Keystone Symposia Conference | Triglycerides and Triglyceride-Rich Particles in Health and Disease

**Meeting has ended.**

View Current Meetings

Meeting Search

Contact Us

Meeting Program

To view program in "24 hour" time (international) click here.

Saturday, January 9
3:00 - 7:30 PM	Registration	Lower Atrium
6:30 - 7:30 PM	Refreshments	Lower Atrium
7:30 - 8:30 PM	Keynote Address Registered attendees for this meeting can view Abstracts for this session starting on 12/09/2009	Gallatin
	Henry N. Ginsberg, Columbia University College of Physicians and Surgeons, USA Increased Assembly and Secretion of Triglyceride-Rich Lipoproteins in Insulin Resistance: Greasing the Path to Atherosclerosis
Sunday, January 10
7:00 - 8:00 AM	Breakfast	Jefferson/Madison
8:00 - 8:15 AM	Welcome and Scientific Introduction Registered attendees for this meeting can view Abstracts for this session starting on 12/09/2009	Gallatin
	Robert H. Eckel, University of Colorado Denver, Anschutz Medical Campus, USA Triglycerides in Health and Disease
8:15 - 11:30 AM	Molecular/Cell Biology and Physiology of Triglyceride Synthesis and TG-Rich Lipoprotein Assembly and Secretion Registered attendees for this meeting can view Abstracts for this session starting on 12/09/2009	Gallatin
	* Mats Rudling, Karolinska Institutet, Sweden
	* Douglas G. Mashek, University of Minnesota, USA
	Rosalind A. Coleman, University of North Carolina at Chapel Hill, USA Metabolic Channeling and Control of Fatty Acid Metabolism
	Bart Staels, Institut Pasteur de Lille, University of Lille 2, France Nuclear Receptor Control of Triglyceride Metabolism
	Edward A. Fisher, New York University School of Medicine, USA Omega-3 Fatty Acids and Lipoprotein Metabolism: Mechanistic Basis for their Clinical Effects
	Mark D. Erion, Merck & Co., Inc., USA Reduction in Plasma and Liver Triglycerides with a Liver-Targeted Thyroid Hormone Receptor-beta Agonist
	John M. Stafford, Vanderbilt University, USA Short Talk: Impaired Inactivation of FoxO1 Contributes to Glucose-Mediated Increases in Serum VLDL
	J. Brandon Dixon, Georgia Institute of Technology, USA Short Talk: Quantifying the Functional Transport of Lipoproteins by Lymphatic Endothelial Cells
11:30 AM-	On Own for Lunch and Recreation
9:20 - 9:40 AM	Coffee Break	Lower Atrium
4:30 - 5:00 PM	Coffee Available	Lower Atrium
5:00 - 7:00 PM	Regulation of Lipolysis in Man and Rodents Registered attendees for this meeting can view Abstracts for this session starting on 12/09/2009	Gallatin
	* Miklos Péterfy, Cedars-Sinai Medical Center, USA
	* Richard Lehner, University of Alberta, Canada
	Rudolf Zechner, University of Graz, Austria Intracellular Lipolysis and the Regulation of Lipid and Lipoprotein Metabolism
	Susan K. Fried, Boston Medical Center, USA Adipokines and Lipolysis in Human Obesity
	Samuel Klein, Washington University School of Medicine, USA Therapeutic Implications of Adipose Tissue and Hepatic Lipid Metabolism in Obesity
	Janna A. van Diepen, Leiden University Medical Center, The Netherlands Short Talk: Hepatocyte-Specific Inflammation Enhances VLDL Production in Mice
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Jefferson/Madison
Monday, January 11
7:00 - 8:00 AM	Breakfast	Jefferson/Madison
8:00 - 11:15 AM	Chylomicron and VLDL Transport, Lipolysis and Tissue-Specific Lipid Partitioning Registered attendees for this meeting can view Abstracts for this session starting on 12/09/2009	Gallatin
	* Andre Bensadoun, Cornell University, USA
	* Rudolf Zechner, University of Graz, Austria
	Ira J. Goldberg, Columbia University, USA LPL Mediated Lipid Uptake
	Nada A. Abumrad, Washington University, USA Free Fatty Acid Uptake and Intracellular Trafficking: Evolving Concepts
	Keith N. Frayn, University of Oxford, UK Triglyceride Uptake into Human Adipose Tissue
	Stephen G. Young, University of California, Los Angeles, USA An Endothelial Cell Protein Required for the Lipolytic Processing of Triglyceride-Rich Lipoproteins
	Jason A. Magida, University of Colorado, Boulder, USA Short Talk: Genetic Heart Disease Results in a Diabetic Phenotype via Reduced Clearance of VLDL-Triglycerides
	Douglas G. Mashek, University of Minnesota, USA Short Talk: Hepatic Adipose Triglyceride Lipase (ATGL) Alters Hepatic Triglyceride Turnover, Fatty Acid Channeling and PPAR-alpha Activity
9:20 - 9:40 AM	Coffee Break	Lower Atrium
11:15 AM- 1:00 PM	Poster Setup	Jefferson/Madison
1:00 - 10:00 PM	Poster Viewing	Jefferson/Madison
4:30 - 5:00 PM	Coffee Available	Lower Atrium
5:00 - 7:00 PM	Genetics and Pathophysiology of Disorders of TG-Rich Lipoprotein Metabolism Registered attendees for this meeting can view Abstracts for this session starting on 12/09/2009	Gallatin
	* John D. Brunzell, University of Washington, USA
	* Leanne Hodson, University of Oxford, UK
	Ruth McPherson, University of Ottawa Heart Institute, Canada Triglycerides and CAD Risk: Insights from Genome-Wide Association Studies
	Alan R. Shuldiner, University of Maryland School of Medicine, USA Genome-Wide Studies of Serum Lipids: Lessons from the Old Order Amish
	Gary F. Lewis, Toronto General Hospital, Canada ApoB Production - Human Gut and Liver
	Michael Olivier, Medical College of Wisconsin, USA Short Talk: Genomic and Proteomic Analysis of Human Dyslipidemia Characteristic of the Metabolic Syndrome
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Jefferson/Madison
7:30 - 10:00 PM	Poster Session 1 Registered attendees for this meeting can view Abstracts for this session starting on 12/09/2009	Jefferson/Madison
Tuesday, January 12
7:00 - 8:00 AM	Breakfast	Jefferson/Madison
8:00 - 11:15 AM	TG-Rich Lipoproteins and Mechanisms of Atherosclerosis Registered attendees for this meeting can view Abstracts for this session starting on 12/09/2009	Gallatin
	* Bo Angelin, Karolinska Institutet, Sweden
	* Lars B. Nielsen, Rigshospitalet, University of Copenhagen, Denmark
	Frank M. Sacks, Harvard School of Public Health, USA Apolipoprotein C-III: Diverse Actions Contributing to Dyslipidemia and Atherosclerosis
	Sudha B. Biddinger, Harvard University, USA Deconvoluting the Metabolic Syndrome: The Role of Hepatic Insulin Resistance
	John C. Rutledge, University of California, Davis, USA Triglyceride-Rich Lipoproteins and Mechanisms of Inflammation and Atherosclerosis
	Clay F. Semenkovich, Washington University School of Medicine, USA Lipids and Stress Responses in the Evolution of Atherosclerosis
	Dagmar Kratky, Medical University of Graz, Austria Short Talk: Adipose Triglyceride Lipase Deficiency Affects Macrophage Morphology and Function and Significantly Reduces Atherosclerosis in LDLR(-/-) Mice
	Nora Gray, University of California, Berkeley, USA Short Talk: The Role of Angiopoietin-like 4 in Glucocorticoid-Regulated Lipid Metabolism
9:20 - 9:40 AM	Coffee Break	Lower Atrium
11:15 AM- 1:00 PM	Poster Setup	Jefferson/Madison
11:15 AM-	On Own for Lunch and Recreation
1:00 - 10:00 PM	Poster Viewing	Jefferson/Madison
4:30 - 5:00 PM	Coffee Available	Lower Atrium
5:00 - 7:00 PM	Population Science on the Relationship between TG-Rich Lipoproteins and ASCVD Registered attendees for this meeting can view Abstracts for this session starting on 12/09/2009	Gallatin
	* Geesje M. Dallinga-Thie, AMC, The Netherlands
	* Ruth McPherson, University of Ottawa Heart Institute, Canada
	Michael H. Criqui, University of California, San Diego, USA Population Studies of TG and ASCVD
	Børge Nordestgaard, University of Copenhagen, Denmark Non-Fasting TGs and CVD Risk
	Elizabeth J. Parks, University of Texas Southwestern Medical Center, USA Dietary Influences on Triglyceride-Rich Lipoprotein Production
	Carlos O. Mendivil, Harvard School of Public Health, USA Short Talk: Tryglicerides in VLDL and LDL with apoC-III are a Strong Coronary Heart Disease Risk Factor when LDL Cholesterol is Low
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Jefferson/Madison
7:30 - 10:00 PM	Poster Session 2 Registered attendees for this meeting can view Abstracts for this session starting on 12/09/2009	Jefferson/Madison
Wednesday, January 13
7:00 - 8:00 AM	Breakfast	Jefferson/Madison
8:00 - 11:15 AM	Therapeutics of Hypertriglyceridemia Registered attendees for this meeting can view Abstracts for this session starting on 12/09/2009	Gallatin
	* Mark W. Sleeman, Regeneron Pharmaceuticals Inc., USA
	* Walter Singleton, Isis Pharmaceuticals, USA
	Rosanne M. Crooke, Isis Pharmaceuticals, USA Development of Novel Antisense Inhibitors for the Treatment of Hypertriglyceridemia
	Dong Cheng, Bristol-Myers Squibb Company, USA Are DGAT Inhibitors a Target for Triglyceride Lowering?
	Matthew T. Flowers, University of Wisconsin, Madison, USA Tissue-Specific Roles for SCD1 in Regulating Obesity
	David Robert Neff, Merck, USA The Potential Role of CETP Inhibition to Manage Dyslipidemia and CVD Risk
	Mark Graham, Isis Pharmaceuticals, USA Short Talk: Antisense Inhibition of Angiopoietin-Like 3 in Rodent Models
	Jennifer L. Lachey, Acceleron Pharma, USA Short Talk: Treatment with a Soluble Activin Receptor Type IIB Attenuates Diet-Induced Obesity in High-Fat Diet-Fed Mice
9:20 - 9:40 AM	Coffee Break	Lower Atrium
11:15 AM-	On Own for Lunch and Recreation
4:30 - 5:00 PM	Coffee Available	Lower Atrium
5:00 - 7:00 PM	Clinical Trials of Triglyceride Lowering and Outcomes Registered attendees for this meeting can view Abstracts for this session starting on 12/09/2009	Gallatin
	* Henry N. Ginsberg, Columbia University College of Physicians and Surgeons, USA
	* Robert H. Eckel, University of Colorado Denver, Anschutz Medical Campus, USA
	Marshall B. Elam, Veterans Affairs Medical Center Memphis, University of Tennessee, USA Fibrates and Cardiovascular Risk Reduction
	Alan Chait, University of Washington School of Medicine, USA Modalities of Triglyceride Lowering in the Prevention and Treatment of Cardiovascular Disease – Role of Niacin
	M. Mahmood Hussain, SUNY Downstate Medical Center, USA Regulation and Targeting of Microsomal Triglyceride Transfer Protein (MTP)
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Jefferson/Madison
8:00 - 11:00 PM	Entertainment	Jefferson/Madison
Thursday, January 14
	Departure
*=Session Chair †=Speaker invited, not yet responded.

We gratefully acknowledge support for this conference from:

Isis Pharmaceuticals, Inc.

The Directors' Fund

These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.

We gratefully acknowledge the generous grant for this conference provided by:

National Institutes of Health
National Heart, Lung, and Blood Institute (NHLBI)
Grant No. 1R13HL099162-01

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We gratefully acknowledge the organizations that provide Keystone Symposia with additional support, such as marketing and advertising...

Click here to view these companies

Triglycerides are important storage molecules that play important roles in lipid and lipoprotein metabolism, insulin action, energy balance, and atherosclerosis. The purpose of this meeting will be to critically examine the broad spectrum of triglyceride biology from the molecular biology of triglyceride biosynthesis in the liver and intestine to lipoprotein assembly and secretion to lipid fuel partitioning to adipose tissue, muscle and the liver. A discussion of the regulation of free fatty acid flux from adipose tissue to the liver by insulin and pro- and anti-inflammatory cytokines will precede a detailed coverage of chylomicron and VLDL transport, intravascular lipolysis and tissue-specific lipid partitioning. A transition to the science and medicine of triglycerides will then occur with expected updates on the understanding of the genetic basis of disorders of triglyceride-rich lipoprotein metabolism and the pathogenesis of atherosclerosis that relate specifically to circulating triglyceride-rich particles. The clinical relevance of hypertriglyceridemia, new insights into the mechanisms of pharmacological treatment of hypertriglyceridemia, and clinical trial evidence pro and con that triglyceride lowering reduces cardiovascular disease risk will follow. The meeting should attract basic, clinical, and population scientists from academia and industry, and will deal with the many issues that remain unclear or controversial surrounding triglycerides and triglyceride rich particles in health and disease.

Triglycerides and Triglyceride-Rich Particles in Health and Disease (A3)